ficerafusp alfa
ficerafusp alfa: sourced relationships with 1 company · 5 clinical trials tracked.
ficerafusp alfa evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
How could ficerafusp alfa → BCAX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Bicara Therapeutics Inc. (BCAX) | Phase 3 |
| Bicara Therapeutics Inc. (BCAX) Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2/Phase 3 |
Clinical Trial Registry Records (5)
Phase I/II Trial of Neoadjuvant Combination of Ficerafusp Alfa, Pembrolizumab, and SBRT for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Primary endpoint: Phase I only: Maximum tolerated dose (MTD) of SBRT in combination with pembrolizumab plus ficerafusp alfa
A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable Squamous Cell Carcinoma of the Head and Neck: a Phase 2 Trial
Primary endpoint: Pathologic Treatment Response-2 (pTR-2) Rate
A Phase II Study of Ficerafusp Alfa (BCA 101) in Combination With Nivolumab in Platinum Refractory Head and Neck Squamous Cell Carcinoma Patients Who Progressed Within 6 Months After Multimodal Treatment for Locally Advanced Disease ( BICARA)
Primary endpoint: Objective response rate (ORR)
A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Primary endpoint: Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.
Frequently asked questions
Which companies have sourced relationships with ficerafusp alfa?
ficerafusp alfa has dated SEC/FDA relationship records for Bicara Therapeutics Inc..
How many clinical trials involve ficerafusp alfa?
BioSniper tracks 5 clinical trials involving ficerafusp alfa.